Drug Profile
Research programme: controlled-release metronidazole - Cosmo Pharmaceuticals
Alternative Names: CB-01-14; CB-01-14 MMX™Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cosmo Pharmaceuticals
- Class Nitroimidazoles
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Intestinal infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Intestinal-infections in USA (PO, Tablet)